Zhongheng Group Subsidiary Lummy Pharmaceutical Plans to Acquire Vitamin D Soft Capsule Drug Registration Approval for 28 Million Yuan

中国证券报··Read original
2▲2 ▼0Impact / 5
Summary · why it matters

Zhongheng Group's controlling subsidiary, Chongqing Lummy Pharmaceutical, plans to acquire the drug registration approval and all global commercial rights for Vitamin D soft capsules from Jiangxi Tianzhihai Pharmaceutical for 28 million yuan. The product is a 0.25 milligram, or 10,000 unit, Vitamin D soft capsule used for preventing or treating diseases related to Vitamin D deficiency. According to data from Morningside Healthcare, from 2023 to 2025, the product's total hospital sales were 1.028 billion yuan, 1.265 billion yuan, and 1.766 billion yuan respectively, while brick-and-mortar pharmacy sales over the same period were 310 million yuan, 283 million yuan, and 310 million yuan. This transaction does not include the national distribution rights already held by Lummy Pharmaceutical's wholly-owned subsidiary, Chongqing Lummy Medical. As of the valuation date of November 30, 2025, the investment value assessed using the income approach was 28.1887 million yuan. After the transaction, Lummy Pharmaceutical will achieve full-chain integration of the product, further enriching its product line and enhancing market competitiveness.

Impact on assets 2

Others▲ · 2 stocks
Chongqing Lummy Pharmaceutical
300006
▲ PositiveCapitalrelevance

Acquires Vitamin D soft capsule registration and global commercial rights for 28 million yuan, achieving full-chain integration.

Off-coverage companies 1

江西天之海药业股份有限公司Private▲ Positive
Capitalrelevance

Sells drug registration approval and global commercial rights for 28 million yuan, generating cash inflow.

© 2026 MarketIVNews